Syncona Limited Issue of Shares Pursuant to the 2017 Dividend

 
TIDMSYNC 
 
15 August 2017 
 
                                Syncona Limited 
 
                 Issue of shares pursuant to the 2017 dividend 
 
The Board of Syncona Limited (the "Company") today announces that a total of 
1,564,683 new ordinary shares will be issued in satisfaction of the payment of 
the Company's 2017 dividend to those qualifying shareholders who did not elect 
to receive the dividend in cash.  The new ordinary shares, when issued, will 
rank pari passu with the existing issued ordinary shares of the Company. 
 
Application has been made to the Financial Conduct Authority for the shares to 
be admitted to the Official List, and to the London Stock Exchange for the 
shares to be admitted to trading and it is expected that dealings will commence 
in the new ordinary shares on 23 August 2017. 
 
[ENDS] 
 
Enquiries 
 
Northern Trust International Fund Administration Services (Guernsey) Limited 
Company Secretary 
Tel:       [phone] 
 
Copies of this announcement and other corporate information can be found on the 
company website at:www.synconaltd.com 
 
About Syncona: 
 
Syncona is a leading FTSE250 healthcare company focused on investing in and 
building global leaders in life science. Our vision is to deliver 
transformational treatments to patients in truly innovative areas of healthcare 
while generating superior returns for shareholders. Our current investment 
portfolio consists of seven high quality companies in life science and a 
leading range of fund investments. 
 
We seek to partner with the best, brightest and most ambitious minds in science 
to build globally competitive businesses. We are established leaders in gene 
therapy, cell therapy and advanced diagnostics, and focus on delivering 
dramatic efficacy for patients in areas of high unmet need. 
 
Our market leading funds portfolio seeks to generate superior returns by 
investing in long only and alternative investment funds. This represents a 
productively deployed evergreen funding base which enables us to take a long 
term approach to investing in life sciences as we target the best new 
opportunities and support our existing portfolio companies to grow and succeed. 
 
Syncona is aligned with two of the premium charitable funders in UK science, 
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both 
of which are significant shareholders in our business.  We make a donation of 
0.3% of Net Asset Value to a range of charities each year. 
 
 
 
END 
 

(END) Dow Jones Newswires

August 15, 2017 06:47 ET (10:47 GMT)